- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07881887
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-mail: LillyTrials@Lilly.com
Undersøgelse Kontakt Backup
- Navn: Physicians interested in becoming principal investigators please contact
- E-mail: clinical_inquiry_hub@lilly.com
Studiesteder
-
-
Arkansas
-
Rogers, Arkansas, Forenede Stater, 72758
- Ikke rekrutterer endnu
- Woodland Research Northwest, LLC
-
Kontakt:
- Telefonnummer: 479-927-3000
-
Ledende efterforsker:
- Timothy Cook
-
-
California
-
Anaheim, California, Forenede Stater, 92801
- Rekruttering
- CenExel ACT
-
Ledende efterforsker:
- Amina Haggag
-
Los Alamitos, California, Forenede Stater, 90720
- Rekruttering
- Collaborative Neuroscience Network - CNS
-
Ledende efterforsker:
- Steven Reynolds
-
Walnut Creek, California, Forenede Stater, 94598
- Rekruttering
- Diablo Clinical Research, Inc.
-
Ledende efterforsker:
- Bonnie Kimmel
-
-
Florida
-
Daytona Beach, Florida, Forenede Stater, 32117
- Rekruttering
- Fortrea Clinical Research Unit
-
Kontakt:
- Telefonnummer: 866-429-3700
-
Ledende efterforsker:
- Chiamaka Iheme
-
Miami, Florida, Forenede Stater, 33417
- Ikke rekrutterer endnu
- Advanced Pharma CR, LLC
-
Ledende efterforsker:
- Simon Abelson
-
Winter Park, Florida, Forenede Stater, 32789
- Rekruttering
- Clinical Site Partners, LLC DBA CSP Orlando
-
Ledende efterforsker:
- ROBERT MEYER
-
-
Georgia
-
Columbus, Georgia, Forenede Stater, 31904
- Rekruttering
- Centricity Research
-
Ledende efterforsker:
- Joseph Surber
-
Kontakt:
- Telefonnummer: 706-321-0495
-
Decatur, Georgia, Forenede Stater, 30030
- Rekruttering
- CenExel iResearch, LLC
-
Ledende efterforsker:
- Kimball Johnson
-
-
Missouri
-
Springfield, Missouri, Forenede Stater, 65802
- Rekruttering
- QPS
-
Ledende efterforsker:
- Leea Reed
-
Kontakt:
- Telefonnummer: 417-893-6161
-
-
New Jersey
-
Marlton, New Jersey, Forenede Stater, 08053
- Rekruttering
- CenExel-HRI
-
Ledende efterforsker:
- Kyle Coupe
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43212
- Rekruttering
- Ohio Clinical Trials
-
Ledende efterforsker:
- Angela Eakin
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75247
- Rekruttering
- Fortrea Clinical Research Unit
-
Ledende efterforsker:
- Archie Bowie
-
San Antonio, Texas, Forenede Stater, 78217
- Rekruttering
- Worldwide Clinical Trials, Inc.
-
Ledende efterforsker:
- Alan Hand
-
-
-
-
-
Singapore, Singapore, 138623
- Ikke rekrutterer endnu
- Lilly Centre for Clinical Pharmacology
-
Kontakt:
- Telefonnummer: 64139811
-
Ledende efterforsker:
- Jennifer Boon Wee
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants must be 21 in Singapore.
- Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent (%) body weight change.
Part A, B, D, and E
-
Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- prediabetes.
Part C
- Have a BMI ≥25.0 kg/m²
- Have a diagnosis of Type 2 Diabetes (T2D) for at least 6 months.
- T2D controlled with diet and exercise alone or are on a stable dose of metformin alone, or in combination with a sodium-glucose co-transporter-2 inhibitor (SGLT-2i), for at least 3 months.
- Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%.
Part D
- To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 of the participants' biological grandparents being of exclusive Chinese descent and born in China.
Part E
- To qualify as Japanese for this study, the participant must be at a minimum third-generation Japanese, defined as having all 4 of the participants' biological grandparents being of exclusive Japanese descent and born in Japan.
Exclusion Criteria:
- Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part A: LY4167586
LY4167586 administered subcutaneously (SC) |
administered SC |
|
Eksperimentel: Part B LY4167586
LY4167586 administered SC |
administered SC |
|
Eksperimentel: Part C LY4167586
LY4167586 administered SC |
administered SC |
|
Eksperimentel: Part D LY4167586
LY4167586 administered SC |
administered SC |
|
Eksperimentel: Part E LY4167586
LY4167586 administered SC |
administered SC |
|
Placebo komparator: Placebo (Part A-E)
Placebo administered SC |
administered SC |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsramme: Baseline through Study Completion (Estimated as Week 89)
|
Baseline through Study Completion (Estimated as Week 89)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
PK: Area Under the Concentration Time Curve (AUC) of LY4167586
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Body Weight Observed Value
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Change from Baseline in Body Weight
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
|
Percent Change from Baseline in Body Weight
Tidsramme: Baseline up to Week 89
|
Baseline up to Week 89
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 27671
- J6L-MC-YIAB (Anden identifikator: Eli Lilly and Company)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .